MARKET ACCESS & REIMBURSEMENT: REAL WORLD EVIDENCE & VALUE DEFINITION

01 Sep 2022
11:00

11:00 – CHAIR INTRODUCTION

Chair: Alexander Natz , Secretary-General, EUCOPE

 

11:05 – FIRESIDE CHAT

Speakers:

Nicola Redfern, Former Vice President Northern Europe, Blue Bird Bio

Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT)

 

11:30 – CASE STUDY: MITIGATING HEMOPHILIA & SICKLE CELL DISEASE DURABLE THERAPY UNCERTAINTIES WITH RWE DRIVEN PAYMENT INNOVATION 

Speaker: Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT) 

 

11:45 – FIRESIDE CHAT

Speakers:

Francesca Pasinelli, Direttore Generale, Fondazione Telethon

 

12:00 – CASE STUDY: AN INTRODUCTION: THE INNOVATION MEDICINES FUND

Speaker: John Spoors, Head of Commercial Medicines Policy Analysis, NHS England

 

12:15 – Q&A SESSION WITH DEEP DIVE SPEAKERS

Speakers:

Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT) 

Francesca Pasinelli, Direttore Generale, Fondazione Telethon

Nina Pinwell, Head of Commercial Operations, NHS England

Speakers

Alexander Natz
Secretary General
EUCOPE
Nicola Redfern
Former Vice President Northern Europe
Bluebird Bio
Mark Trusheim
Strategic Director, NEWDIGS and Visiting Scientist,
Massachusetts Institute of Technology (MIT)
Francesca Pasinelli
Director General
Fondazione Telethon
John Spoors
Head of Commercial Medicines Policy Analysis
NHS England